The testosterone replacement therapy for prostate cancer patients: Time to take the leap?
hypogonadism
prostate cancer
radiotherapy
recurrence
testosterone replacement therapy
Journal
Andrology
ISSN: 2047-2927
Titre abrégé: Andrology
Pays: England
ID NLM: 101585129
Informations de publication
Date de publication:
09 May 2024
09 May 2024
Historique:
revised:
02
04
2024
received:
12
02
2024
accepted:
28
04
2024
medline:
10
5
2024
pubmed:
10
5
2024
entrez:
9
5
2024
Statut:
aheadofprint
Résumé
The advent of new systemic therapies resulted in a significant decrease in prostate cancer (PCa) death in the past decades. It comes at the cost of an increase in the proportion of men living with long-term treatment-induced hypogonadism. In a population of men with no history of PCa, the testosterone replacement therapy (TRT) proved its ability to both improve erectile function and reduce cardiovascular morbidity, translating into an improved overall survival. Whether TRT is safe and efficient in PCa patients remains an open question. Here, we present an overview on the safety of TRT for PCa patients and discuss the optimal population eligible for TRT after the PCa treatment.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© 2024 American Society of Andrology and European Academy of Andrology.
Références
Ong WL, Wilhalme H, Millar JL, et al. Testosterone recovery following androgen suppression and prostate radiotherapy (TRANSPORT): updated individual patient data meta‐analyses from the MARCAP consortium. J Clin Oncol. 2023;41:5096‐5096. doi:10.1200/JCO.2023.41.16_suppl.5096
Izard MA. Leydig cell function and radiation: a review of the literature. Radiother Oncol J Eur Soc Ther Radiol Oncol. 1995;34:1‐8. doi:10.1016/0167‐8140(94)01501‐s
Saad F, Caliber M, Doros G, Haider KS, Haider A. Long‐term treatment with testosterone undecanoate injections in men with hypogonadism alleviates erectile dysfunction and reduces risk of major adverse cardiovascular events, prostate cancer, and mortality. Aging Male. 2020;23:81‐92. doi:10.1080/13685538.2019.1575354
Endogenous Hormones and Prostate Cancer Collaborative Group, Roddam AW, Allen NE, Appleby P, Key TJ. Endogenous sex hormones and prostate cancer: a collaborative analysis of 18 prospective studies. J Natl Cancer Inst. 2008;100:170‐183. doi:10.1093/jnci/djm323
Neuzillet Y, Raynaud J‐P, Dreyfus J‐F, et al. Aggressiveness of localized prostate cancer: the key value of testosterone deficiency evaluated by both total and bioavailable testosterone: androCan study results. Horm Cancer. 2019;10:36‐44. doi:10.1007/s12672‐018‐0351‐8
Morgentaler A, Traish AM. Shifting the paradigm of testosterone and prostate cancer: the saturation model and the limits of androgen‐dependent growth. Eur Urol. 2009;55:310‐320. doi:10.1016/j.eururo.2008.09.024
Kumar R, Sena LA, Denmeade SR, Kachhap S. The testosterone paradox of advanced prostate cancer: mechanistic insights and clinical implications. Nat Rev Urol. 2023;20:265‐278. doi:10.1038/s41585‐022‐00686‐y
Lenfant L, Leon P, Cancel‐Tassin G, et al. Testosterone replacement therapy (TRT) and prostate cancer: an updated systematic review with a focus on previous or active localized prostate cancer. Urol Oncol Semin Orig Investig. 2020;38:661‐670. doi:10.1016/j.urolonc.2020.04.008
Hashimoto T, Rahul K, Takeda T, et al. Prostate magnetic resonance imaging findings in patients treated for testosterone deficiency while on active surveillance for low‐risk prostate cancer. Urol Oncol. 2016;34:530.e9‐530.e14. doi:10.1016/j.urolonc.2016.07.004
Khera M, Grober ED, Najari B, et al. Testosterone replacement therapy following radical prostatectomy. J Sex Med. 2009;6:1165‐1170. doi:10.1111/j.1743‐6109.2009.01161.x
Ory J, Flannigan R, Lundeen C, Huang JG, Pommerville P, Goldenberg SL. Testosterone therapy in patients with treated and untreated prostate cancer: impact on oncologic outcomes. J Urol. 2016;196:1082‐1089. doi:10.1016/j.juro.2016.04.069
Denmeade SR, Wang H, Agarwal N, et al. TRANSFORMER: a randomized phase II study comparing bipolar androgen therapy versus enzalutamide in asymptomatic men with castration‐resistant metastatic prostate cancer. J Clin Oncol. 2021;39:1371‐1382. doi:10.1200/JCO.20.02759
Wang C, Nieschlag E, Swerdloff R, et al. Investigation, treatment and monitoring of late‐onset hypogonadism in males: ISA, ISSAM, EAU, EAA and ASA recommendations. Eur J Endocrinol. 2008;159:507‐514. doi:10.1530/EJE‐08‐0601
Tombal BF, Gomez‐Veiga F, Gomez‐Ferrer A, et al. A phase 2 randomized open‐label study of oral darolutamide monotherapy versus androgen deprivation therapy in men with hormone‐sensitive prostate cancer (EORTC‐GUCG 1532). Eur Urol Oncol. 2024:S2588931124000348. doi:10.1016/j.euo.2024.01.009